Creating a database for pediatric CNS tumors in Asia
National Cancer Center Korea
This study is creating a database to collect information about children with CNS germinoma tumors in Asia to help improve treatment and care for them.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 400 (estimated) |
| Sex | All |
| Sponsor | National Cancer Center, Korea Government |
| Locations | 1 site (Goyang-si, Gyeonggi-do) |
| Trial ID | NCT05982691 on ClinicalTrials.gov |
What this trial studies
This project aims to establish an Asian consortium focused on collecting data related to pediatric central nervous system (CNS) tumors, specifically CNS germinoma. The study will begin by registering patients diagnosed with CNS germinoma from 2022 to 2027 and will develop clinical protocols tailored for pediatric CNS tumors in Asia. The consortium will also analyze medical records until 2030 and conduct interim assessments to ensure data quality and integrity. The final analysis of treatment outcomes is projected for 2032.
Who should consider this trial
Good fit: Ideal candidates include patients aged 0 to 40 diagnosed with CNS germinoma who consent to participate in the research.
Not a fit: Patients who do not have a diagnosis of CNS germinoma or who do not consent to participate will not benefit from this study.
Why it matters
Potential benefit: If successful, this initiative could enhance understanding and treatment of pediatric CNS tumors in Asia, leading to improved patient outcomes.
How similar studies have performed: While this approach is collaborative and data-driven, similar studies have shown promise in improving treatment protocols for CNS tumors, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria:
* A patient who was diagnosed with CNS GCT and agreed to participate in the research between 2022-2027.
* Patients diagnosed between 2016-2022 can be enrolled if the participating institute has IRB approval for recruiting these patients as separate IRB document (Seoul Asan Hospital) or by comprehensive IRB document (Singapore NCC, Taiwan Medical University), or by recruitment on the basis of acquirement of the consent form for research (NCC, Korea).
* The age at the time of diagnosis is 0\< ≤40 years
* A patent who has been diagnosed with the relevant tumor via an operation or a biopsy ⑤ In the case of CNS germinoma, a biopsy may not have been performed on a patient. In this case, the patient may register as germinoma if he or she meets the following criteria: -Germinoma is strongly suspected radiologically, and a tumor marker from serum or cerebrospinal fluid (CSF) has not increased above the institute's reference normal value; -Germinoma is suspected radiologically, and a tumor marker from serum or CSF has elevated above the institute's reference normal value (tumor markers may be AFP or hCG)
Exclusion Criteria:
① The patient or the guardian of the patient did not consent to participate.
Where this trial is running
Goyang-si, Gyeonggi-do
- National Cancer Center, Korea — Goyang-si, Gyeonggi-do, South Korea (Recruiting)
Study contacts
- Principal investigator: Joo-young Kim, M.D., Ph.D. — National Cancer Center
- Study coordinator: Joo-young Kim, M.D., Ph.D.
- Email: jooyoungcasa@ncc.re.kr
- Phone: +82 31 920 1724
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.